Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis to spin off Sandoz, list it in Zurich
01:23am, Thursday, 25'th Aug 2022
Novartis said on Thursday it would spin off Sandoz and list it on the Swiss stock exchange to create the No.1 European generics company.
Don't Look for Alcon's Acquisition to Boost Share Price in Short Term
04:02pm, Wednesday, 24'th Aug 2022
Most investors would probably be pleased with a share price gain of 33% in just over three years, but more than 50% sounds a lot better.
Aerie (AERI) to be Acquired by Alcon for $770M, Shares Up
03:28pm, Tuesday, 23'rd Aug 2022 Zacks Investment Research
Aerie (AERI) enters into an agreement with Alcon to be acquired for $770 million. Shares gain.
7 High-Yield Dividend Aristocrats For The Next Market Crash
11:00am, Tuesday, 23'rd Aug 2022 Seeking Alpha
These 7 stock picks are among the world's best high-yield, low-volatility, quality aristocrats that can help you get through the next market crash. Read more.
Novartis: Undervalued Swiss Pharma Giant
03:51am, Sunday, 21'st Aug 2022
Novartis is a global healthcare company with a research-driven focus on pharmaceuticals, both prescription-based and generic. Valued at a one-year forward P/E of < x14, Novartis trades at a discount t
3 Dangerous Dividend Aristocrats To Avoid And 6 High-Yield Aristocrats To Buy Instead
11:00am, Saturday, 20'th Aug 2022 Seeking Alpha
EFAD, EUDV, and EMDV are three aristocratic ETFs that have delivered terrible inflation-adjusted returns. Check out our 6 high-yield aristocrats here.
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
01:07pm, Friday, 19'th Aug 2022 Zacks Investment Research
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN)
Caribou's Blood Cancer Candidate Shows Response Rates Better Than Novartis,' This Analyst Writes
06:14pm, Thursday, 18'th Aug 2022 Benzinga
Last week, Caribou Biosciences Inc (NASDAQ: CRBU) announced Q2 earnings and provided updated results from the Phase 1 ANTLER trial of the company's lead asset—CB-010 for relapsed or refractory B
Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint
04:00pm, Tuesday, 16'th Aug 2022 Zacks Investment Research
Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.
Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint
01:33pm, Tuesday, 16'th Aug 2022
Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.
Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision
02:05pm, Monday, 15'th Aug 2022 Zacks Investment Research
Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.
4 High-Yield Stocks for Dividend Investors
04:02pm, Friday, 12'th Aug 2022
PPL Corp, Duke Energy Corp, Novartis AG and Carlyle Group Inc. are topping the U.S. market average in terms of dividend yields.
This Nasal Spray For Eye Disease Stock Is 'Attractive', Has Potential 160% Upside
07:11pm, Thursday, 11'th Aug 2022 Benzinga
Chardan initiated coverage on Oyster Point Pharma Inc (NASDAQ: OYST) with a Buy rating and a price target of $22.
The lead product, Tyrvaya, was approved in October 2021 and generated $1.2 million
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
12:14pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
7 Cheap Biotech Stocks to Buy Now
04:42pm, Wednesday, 03'rd Aug 2022
Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.
